Pharma BD Deal Intelligence
Bayer's $2 billion acquisition of Asklepios BioPharmaceuticals for its investigational gene therapy pipeline reads as a mixed outcome: a bet on platform potential rather than a proven asset, and years later the underlying compounds remain undisclosed and unadvanced in the public record.
Bayer acquired AskBio for $2B for investigational gene therapy compounds.
Bayer to buy AskBio for $2B to become a gene therapy player gaining AAV platform for Pompe and Parkinson.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Bayer acquired AskBio for $2B for investigational gene therapy compounds.
960K US cases/yr · $12.0B Global HF Therapeutics (2024)
Gene therapy for heart failure targets pathways to improve cardiac contractility, reduce fibrosis, or promote angiogenesis. AskBio (Bayer) is developing AAV-based cardiac gene therapies alongside its neurology pipeline.
Bayer acquired AskBio for $4B (upfront + milestones) to access its AAV gene therapy platform. AB-1002 targets heart failure. The cardiac gene therapy field faces challenges in vector delivery to sufficient cardiomyocytes, immune response, and demonstrating durable benefit. Tenaya Therapeutics and Rocket Pharmaceuticals also have cardiac gene therapy programs.
90K US cases/yr · $6.6B Global PD Therapeutics (2024)
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized pathologically by loss of dopaminergic neurons in the substantia nigra pars compacta and accumulation of alpha-synuclein in Lewy bodies. It affects approximately 1 million people in the United States, with incidence rising sharply after age 60. The cardinal motor features are bradykinesia with rest tremor, rigidity, and postural instability; onset is typically asymmetric. Non-motor features — hyposmia, REM sleep behavior disorder, constipation, depression and anxiety, cognitive impairment, autonomic dysfunction, and hallucinations — often precede motor symptoms by years and drive much of the disease burden over time. Diagnosis is clinical, supported by response to dopaminergic therapy and, when needed, DaT-SPECT imaging. Management is symptomatic and multimodal: levodopa/carbidopa remains the most effective symptomatic therapy, complemented by dopamine agonists, MAO-B and COMT inhibitors, amantadine for dyskinesia, and advanced options including subcutaneous or intestinal levodopa infusion, apomorphine, and deep brain stimulation for motor fluctuations. Multidisciplinary care including physical, occupational, and speech therapy, and management of cognitive, psychiatric, and autonomic non-motor features, is essential.
Neurocrine/Voyager VY-AADC and Bayer/AskBio AB-1005 both target AADC gene delivery via AAV vectors. Challenges include surgical delivery, immune response to AAV, and durability of expression. Early clinical data has shown improvement in motor function and reduced levodopa requirements.
Bayer completed $2B acquisition of AskBio, gaining AAV gene therapy platform and pipeline for Parkinson's, heart failure, and neuromuscular diseases.
Bayer restructured AskBio gene therapy programs, narrowing focus after industry-wide AAV manufacturing and clinical challenges.
AskBio faces gene therapy headwinds: manufacturing complexity, clinical setbacks, slow translation. Bayer narrowed pipeline significantly from original vision.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Asklepios BioPharmaceuticals (this deal) | 2020 | $2.0B | 49 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2020 deals · Bayer AG deals · Cardiovascular deals